According to the latest data from the Hong Kong Stock Exchange, on January 28, JPMorgan increased its stake in Innovent Bio (01801) by 198,871 shares, with a transaction price of HK$83.829 per share, amounting to a total of approximately HK$16.67 million. Following this acquisition, its latest shareholding quantity stands at approximately 86.7841 million shares, representing a 5% stake in the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.